[] previous 4 weeks each for the two sodium/24 hours risk HT group involving intervention: groups: during high sodium 1): their parents phase & 68.4mmol 1. 80mmol SBP: to be either sodium/24 hours tablets/day (SEM: 0.82, at a low during low sodium 95% CI: -2.11, genetic risk phase 2. Placebo tablets as 1.11) of being at Group 2 (high risk All participants hypertension DBP: 1.4mmHg low risk for HT): 130.6mmol were provided with (based on (SEM: 0.9, of sodium/24 hours dietary advice to their 95%CI: -0.36, during high sodium reduce sodium parent’s BP) 3.16) phase & 56.3mmol intake for the or a high risk (n=31) sodium/24 hours duration of the (for high risk HT of during low sodium study group 2): hypertension phase SBP: -1.4mmHg as (SEM:0.74, being at 95%CI: high risk of DBP: 1.2mmHg (SEM: 0.93, (n=35) 95%CI: Key features for bias assessment of randomised trials
[] previous involving their parents to be either at a low genetic risk of hypertension (based on their parent’s BP) or a high risk of hypertension 4 weeks each intervention: 1. 80mmol tablets/day 2. Placebo tablets All participants were provided with dietary advice to reduce sodium intake for the duration of the study for the two groups: as being at low risk of (n=31) as being at high risk of (n=35) sodium/24 hours during high sodium phase & 68.4mmol sodium/24 hours during low sodium phase Group 2 (high risk for HT): 130.6mmol sodium/24 hours during high sodium phase & 56.3mmol sodium/24 hours during low sodium phase risk HT group 1): SBP: (SEM: 0.82, 95% CI: -2.11, 1.11) DBP: 1.4mmHg (SEM: 0.9, 95%CI: -0.36, 3.16) (for high risk HT group 2): SBP: -1.4mmHg (SEM:0.74, 95%CI: DBP: 1.2mmHg (SEM: 0.93, 95%CI: Key features for bias assessment of randomised trials